Variations in the Wnt/ β -Catenin Pathway Key Genes as Predictors of Cervical Cancer Susceptibility [Corrigendum]

Wang B, Wang M, Li X, Yang M, Liu L. *Pharmacogenomics Pers Med*. 2020;13:157–165.

Page 157, Abstract, Results section, the text “The mutant alleles of rs3864004 (A) and rs2293303 (T) located in CTNNB1 showed 1.513 (1.038–2.207), and 1.654 (1.020–2.683) fold increased risk of cervical cancer, respectively” should read “The mutant alleles of rs3864004 (A) and rs2293303 (T) located in CTNNB1 showed 0.661 (0.453–0.964), and 0.605 (0.373–0.981) fold risk of cervical cancer, respectively”.

Page 160, Results, Association Analysis of Eight Polymorphisms with Cervical Cancer section, the text “Compared with the healthy control group, the rs3864004

A allele (OR=1.513, 95% CI=1.038–2.207, P=0.031) of the CTNNB1 gene showed significant differences in the cervical cancer group. The minor allele (T) for rs2293303 was positively associated with a higher risk for cervical cancer development (OR=1.654, 95% CI=1.020–2.683, P=0.040, [Table 3](#))” should read “Compared with the healthy control group, the rs3864004 A allele (OR=0.661, 95% CI=0.453–0.964, P=0.031) of the CTNNB1 gene showed significant differences in the cervical cancer group. The minor allele (T) for rs2293303 was positively associated with a lower risk for cervical cancer development (OR=0.605, 95% CI=0.373–0.981, P=0.040, [Table 3](#))”.

[Table 3](#) on page 161, the OR (95% CI) values are incorrect. The correct [Table 3](#) is shown below.

Table 3 Association between alleles frequencies and cervical cancer risk

Gene	SNP ID	Allele	Frequency, No. (%)		P	OR (95% CI)
			Cases (n=147)	Controls (n=158)		
APC	rs454886	G	175 (59.5)	192 (60.8)	Ref.	Ref.
		A	119 (40.5)	124 (39.2)	0.755	1.053 (0.761–1.456)
GSK3 β	rs3755557	T	259 (88.1)	275 (87.0)	Ref.	Ref.
		A	35 (11.9)	41 (13.0)	0.689	0.906 (0.560–1.468)
CTNNB1	rs11564475	A	257 (87.4)	277 (87.7)	Ref.	Ref.
		G	37 (12.6)	39 (12.3)	0.928	1.023 (0.632–1.654)
	rs1798802	G	220 (74.8)	214 (67.7)	Ref.	Ref.
		A	74 (25.2)	102 (32.3)	0.053	0.706 (0.496–1.005)
	rs3864004	G	235 (79.9)	229 (72.5)	Ref.	Ref.
		A	59 (20.1)	87 (27.5)	0.031	0.661 (0.453–0.964)
	rs4135385	G	170 (57.8)	164 (51.9)	Ref.	Ref.
		A	124 (42.2)	152 (48.1)	0.142	0.787 (0.572–1.084)
	rs2293303	C	264 (89.8)	266 (84.2)	Ref.	Ref.
		T	30 (10.2)	50 (15.8)	0.040	0.605 (0.373–0.981)
TCF7L2	rs7903146	C	286 (0.973)	299 (0.946)	Ref.	Ref.
		T	8 (0.027)	17 (0.054)	0.098	0.492 (0.209–1.158)

Notes: P $\leq$ 0.05 is considered as significant. Bold values indicate significant differences.

Abbreviations: OR, odds ratio; CI, confidence interval.

Page 162, Discussion, second paragraph, “In the single-locus analysis, we identified that mutant alleles of rs3864004 (A) and rs2293303 (T) might be risk factors for cervical cancer” should read “In the single-locus analysis, we identified that mutant alleles of rs3864004 (A)

and rs2293303 (T) might be protective factors for cervical cancer”.

The authors apologize for these errors and advise they do not affect the scientific conclusions of the paper.

Pharmacogenomics and Personalized Medicine

Dovepress

Publish your work in this journal

Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability. This journal is indexed

on the American Chemical Society's Chemical Abstracts Service (CAS). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journal>